MedTrace Logo

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2015-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.

Conditions

Interventions

DRUG

Rivaroxaban

Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin

DRUG

Warfarin and Enoxaparin

Historical Control

Sponsors & Collaborators

  • Cook County Hospital

    collaborator OTHER

  • Cook County Health

    lead OTHER_GOV

Principal Investigators

  • Pete Antonopoulos, PharmD · Cook County Hospital

  • Asinul Ansari, MD · Cook County Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747746 on ClinicalTrials.gov